Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Transgene and Tasly JV Starts Operations with Four Transgene Molecules

publication date: Jul 27, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
The JV established by France’s Transgene and Tasly Pharma of China announced that Transgene is contributing China rights to four biotech immunotherapeutic candidates to the JV. The JV will be capitalized with $3.2 million from Transgene and $6.6 million from Tasly. The value of Transgene’s drug IP evens its investment in the 50:50 partnership with Tasly’s. Transgene develops immunotherapeutic products aimed at cancer and infectious diseases. More details....

Stock Symbols: (Euronext: TNG) (SHA: 600535)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners